Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have made it very clear their intention is to be bought out or at a minimum parter up. I think within 6 months after results we will be hearing huge news (if they are good fo course).
Stock will pop up 100-150% on great results. This is much more important than Phase 3.
Thanks! I did see someone post an email from IR and they said they are still on track for Mid April, so we shall see.
I agree, this could be a game changing drug!
It's still an 11B market. And also the issues you are referring to are from longterm use. NSAIDS are obviously very effective, but even in short term use (days and weeks) can cause ulcers. This drug has solved that problem. Furthermore, if you looked into it more, you would see this drug makes naproxen much more powerful (and safer), so you have to take about 1/4 the normal dose of naproxen.
So I have to disagree with you. I don't think NSAIDS are going anywhere, anytime soon and at least there could be a much safer version of it soon.
Thanks, I agree with you as well. I wouldn't call the share count terrible, but It's certainly not great. I would call it in the middle. But thus is financing/dilution for a small bio like this.
The important part is market cap and i think this is very small for what they potentially have.
Best of luck, exciting times ahead!
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
https://antibethera.com/wp-content/uploads/2020/02/Antibe-Investor-Presentation-February-2020.pdf
I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.
Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace
Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)
Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF
https://antibethera.com/wp-content/uploads/2020/02/Antibe-Investor-Presentation-February-2020.pdf
Excellent news.
I hear ya and agree. Best of luck to us!
Yeah they are. CEO just stated they want to get ion it around Sept. 2020. I have very high hopes for the year, but $4 is pushing it. And they have to be safe and maintain that price, so an RS is very likely. A rare time it is fine with me.
Excited to uplist and get more volume, more respect and real BIG investors.
Yup, can't wait! Although the volume has finally gone wayyyyy up, being on the Nasdaq will help very much with volume. And then hedge funds and institutions will finally be able to invest.
They will have to do a small RS most likely, which is fine with me, because it is not for dilution or a huge share count, but strictly to uplist.
There is a tiny chance they could reach and maintain $4 naturally, which would be amazing obviously.
Long $ATBPF !!!!!!!!
Kind of old, but some very interesting info in here:
https://www.outsourcing-pharma.com/Article/2019/12/16/Antibe-engages-global-CMO-to-support-planned-pain-drug-partnership
Sure seems like some people know something we don't. Wasn't expecting a rally until the final enrollment was out, but i'll take it!
Yayyyyyy!
Or the doors are closing and we just lost everything. Sucks.
Halted....Hopefully the buyout is going through and part of the conditions were for the CEO to resign.
Ha! Good one. Buyout is coming any day now IMO.
Totally agree, Dionymed is obviously just their corporate name, not brand name, but still terrible, not helping their case at all. CHILL would be way better.
Just saw a massive billboard for CHILL in downtown San Francisco, very prominent.
Smart money knows a buyout is coming, probably in the next few weeks. Nice high of day close too! Looking very bullish.
I think that's why the CFO was fired. He blew it. They just got another $3M loan, so they should be able to at least make payments and get current.
I agree they should have done a PP when the PPS was over $1. OS is very low and the float is insanely low at 20M.
For the almost guaranteed chance of a buyout down here this is a great buy IMO
99% chance a buyout is coming in the next month. They basically admitted it in the last PR. Revs could be 70-80M this year.
100M revs next year possible. Same as Aurora and Canopy HAHA! 6B MC vs DYMEF at 10M!!!
BUYOUT COMING! Buy while it's dirt cheap! Market cap right now is the same as hard assets and the same as their quarterly Revs!!!! Insanely undervalued!
The Company requested a halt in trading when there was a strong possibility it would announce a transaction in the ensuing days; however, multiple other potential transactions of various types have surfaced, all of which require more time for evaluation. The Company is not able to say with certainty whether any of these transactions will be considered, or if considered, entered into, and will provide an update in due course. Any transaction may be subject to definitive documentation, corporate approvals and other regulatory and third-party approvals.
Based on their hints in the last PR and lots of rumors swirling around they are getting bought out. I have a feeling who ever is buying them wanted a shake up and that's why they had to restructure, do layoffs etc
I couldn't see it less than being for $1, maybe even $2 or $3. A dollar buy out would only be about $65M and they are worth way more than that.
Me neither. With todays action this is the most undervalued cannabis stock in the sector. By far. I said this 2 weeks ago and now it is beyond undervalued. They have 15M in hard assets, about 30M in goodwill and revs this year will be around 60-70M I think.
And there is barely any shares, only 20M float!!! PART OF THE REASON IT'S SO VOLATILE. I just have no idea who the Fawk was selling today at such low prices? Why sell at such a huge loss?
Welp, that was a huge donkey punch. Ouch. Sounds like they might be bought out soon.
Dang, WTH happened here? I'm already down like 35% Yikes ha. Now it just seems beyond undervalued.
Yeah, I kept seeing 25M on my TD, OTC markets, etc. But IR got back to me and you are correct, 67M outstanding. But the float is still very low.
I thought I saw two $2M PP draws. But maybe I'm mistaken.
Who is the strategic investor and what's that about? Thanks, sorry new here, but am blown away by how under the radar this is.
Last week I stumbled upon DionyMed Brands. (CSE: DYME) (OTC: DYMEF) "DionyMed is a multi-state cannabis brands platform, supporting cultivators, manufacturers and award-winning brands in the medical and adult-use cannabis markets."
I have been investing and trading in the Cannabis sector since it's start and have never seen a more undervalued company.
Current market cap is a ridiculously low $25M, with a very low float, 18.5M!!! Their assets total $55M, including their Goodwill assets, which I always take with a grain of salt. But real assets total about $15M.
Management team is very legit:
https://ir.dionymed.com/company-information/management-team
Let's look at their recent financials:
"Total gross revenues of product processed for the three and six months ended June 30, 2019 are $12.7 million and $34.4 million representing increases of 830% and 1,333% of the respective periods in 2018."
So it's safe to say revs for the year could be up to $70-80M. At it's current market cap, that gives it a price to earnings ratio of about -3!!!!! Most cannabis companies have 20, 30, 50, 100 PE ratio!!! ACB has a 50 for example. I've never seen a negative PE ratio in the Cannabis sector ha
They own CHILL, which is a EAZE type delivery platform. I just saw a massive CHILL billboard in downtown San Francisco. They are partnered with some very well known Cali brands like Zkittles, Lemon Tree, Canna Strips, CBDALIVE, etc.
Zkittles is one of the best strains/brands out right now, if you didn't know. This partnership alone is huge!
They just closed this huge deal with IIPR:
https://ir.dionymed.com/news-events/press-releases/detail/32/dionymed-announces-close-of-acquisition-with-innovative
Overall, this company is making great moves, partnered with some of the best brands in CA and is clearly under the radar right now.
Negatives: Low volume, probably a year or two from being profitable and has $20M left in a PP, with underwriters getting a 10-15% discount. They appear to be selling in $2M tranches, which coupled with its low exposure/volume has driven the price down for a year straight. IMHO this has provided a great buy in opportunity.
In a land of overvalued Cannabis stocks, I think this is highly undervalued and worth looking at. Similar MSOs have market caps 20-40X as high.
Disclaimer: I hold shares and will be buying on dips, like today.
https://ir.dionymed.com/news-events/press-releases/detail/32/dionymed-announces-close-of-acquisition-with-innovative
TGOD already responded. A large investor swooped up the shares. So this is great news! We have a huge investor going long and now ACB doesn't get discounted product! Win win!
Now ACB can go overpay for another asset LOL
Of course it pops right before I buy some, god damnit haha
You guys couldn't wait for me to get some funds ready to buy this? I see how it is! ha. Nice pop.
Thanks. So a lot more to go. Just trying to figure out this stock, just found it. The MC seems ridiculously low, like out of this world low for its revs, legitimacy, share count, etc Especially compared to most cannabis stocks.
The only thing I can see holding this down is the PP.